137 related articles for article (PubMed ID: 11270618)
1. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Narita M; Suzuki T
Life Sci; 2001 Mar; 68(15):1717-25. PubMed ID: 11270618
[TBL] [Abstract][Full Text] [Related]
2. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
[TBL] [Abstract][Full Text] [Related]
3. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
Mori T; Nomura M; Nagase H; Narita M; Suzuki T
Psychopharmacology (Berl); 2002 Apr; 161(1):17-22. PubMed ID: 11967626
[TBL] [Abstract][Full Text] [Related]
4. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
[TBL] [Abstract][Full Text] [Related]
5. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
Endoh T; Tajima A; Izumimoto N; Suzuki T; Saitoh A; Suzuki T; Narita M; Kamei J; Tseng LF; Mizoguchi H; Nagase H
Jpn J Pharmacol; 2001 Mar; 85(3):282-90. PubMed ID: 11325021
[TBL] [Abstract][Full Text] [Related]
6. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
Endoh T; Matsuura H; Tajima A; Izumimoto N; Tajima C; Suzuki T; Saitoh A; Suzuki T; Narita M; Tseng L; Nagase H
Life Sci; 1999; 65(16):1685-94. PubMed ID: 10573186
[TBL] [Abstract][Full Text] [Related]
7. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Yamazaki M; Narita M; Suzuki T
Life Sci; 2000; 66(25):PL353-8. PubMed ID: 10894094
[TBL] [Abstract][Full Text] [Related]
8. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
9. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
10. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
[TBL] [Abstract][Full Text] [Related]
11. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
[TBL] [Abstract][Full Text] [Related]
12. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state.
Narita M; Kishimoto Y; Ise Y; Yajima Y; Misawa K; Suzuki T
Neuropsychopharmacology; 2005 Jan; 30(1):111-8. PubMed ID: 15257306
[TBL] [Abstract][Full Text] [Related]
14. Effects of Intrathecal κ-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception in Mice.
Sakakihara M; Imamachi N; Saito Y
Reg Anesth Pain Med; 2016; 41(1):69-74. PubMed ID: 26587674
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the antinociceptive effects of TRK-820 in the rat.
Endoh T; Tajima A; Suzuki T; Kamei J; Narita M; Tseng L; Nagase H
Eur J Pharmacol; 2000 Jan; 387(2):133-40. PubMed ID: 10650153
[TBL] [Abstract][Full Text] [Related]
16. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
[TBL] [Abstract][Full Text] [Related]
17. Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice.
Suzuki T; Tsuji M; Mori T; Misawa M; Endoh T; Nagase H
J Pharmacol Exp Ther; 1996 Oct; 279(1):177-85. PubMed ID: 8858991
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
[TBL] [Abstract][Full Text] [Related]
19. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
[TBL] [Abstract][Full Text] [Related]
20. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Kreek MJ
Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
